SCI Pharmtech, Inc. (TPE:4119)

Taiwan · Delayed Price · Currency is TWD

52.00

-0.20 (-0.38%)

Mar 9, 2026, 1:30 PM CST

-39.18% (1Y)

Market Cap	6.21B
Revenue (ttm)	1.34B
Net Income (ttm)	107.37M
Shares Out	119.51M
EPS (ttm)	0.90
PE Ratio	57.78
Forward PE	n/a
Dividend	1.50 (2.87%)
Ex-Dividend Date	Jul 1, 2025

Volume	249,150
Average Volume	153,646
Open	50.10
Previous Close	52.20
Day's Range	50.10 - 52.40
52-Week Range	46.85 - 86.00
Beta	0.13
RSI	49.76
Earnings Date	Mar 18, 2026

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, an... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1987

Employees 239

Stock Exchange Taiwan Stock Exchange

Ticker Symbol 4119

Full Company Profile

Financial Performance

In 2025, SCI Pharmtech's revenue was 1.34 billion, a decrease of -11.81% compared to the previous year's 1.52 billion. Earnings were 107.37 million, a decrease of -79.92%.

Financial Statements

News

There is no news available yet.